Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

31 Mar 2020

Abstract excerpt

Current objectives regarding treatment of acute myeloid leukemia (AML) include achieving complete remission (CR) by clinicopathological criteria followed by interrogation for the presence of minimal/measurable residual disease (MRD) by molecular genetic and/or flow cytometric techniques. Although advances in molecular genetic technologies have enabled highly sensitive detection of AML-associated mutations and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32232484
DOI: 10.1182/blood.2019004770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemiaPMID 32232484Read ↗

Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual DiseaseSemantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemiaSemantic proximity Read ↗

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity Read ↗

Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.Semantic proximity Read ↗

Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation SequencingSemantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.Semantic proximity Read ↗

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemiaSemantic proximity Read ↗

Tumor heterogeneity makes AML a “moving target” for detection of residual diseaseSemantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.